Cox-2 selective nonsteroidal anti-inflammatory drugs

The VIGOR (Vioxx Gastrointestinal Outcomes Research) trial, "which was the making of Merck's drug rofecoxib (Vioxx)," [38] was at the center of a dispute about the ethics of medical journals. VIGOR trial,1 was a trial in which over 8000 patients were randomized to receive either naproxen or rofecoxib (Vioxx), a Cox-2 inhibitor that Merck hoped would have fewer gastrointestinal side effects." [38] Both publications concluded that COX-2 specific NSAIDs were associated with significantly fewer adverse gastrointestinal effects. In the CLASS trial comparing Celebrex 800 mg/day to ibuprofen 2400 mg/day and diclofenac 150 mg/day for osteoarthritis or rheumatoid arthritis for six months, Celebrex was associated with significantly fewer upper gastrointestinal complications (% vs. %, P=), with no significant difference in incidence of cardiovascular events in patients not taking aspirin for cardiovascular prophylaxis .

Cox-2 selective nonsteroidal anti-inflammatory drugs

cox-2 selective nonsteroidal anti-inflammatory drugs

Media:

cox-2 selective nonsteroidal anti-inflammatory drugscox-2 selective nonsteroidal anti-inflammatory drugscox-2 selective nonsteroidal anti-inflammatory drugscox-2 selective nonsteroidal anti-inflammatory drugscox-2 selective nonsteroidal anti-inflammatory drugs

http://buy-steroids.org